XML 41 R35.htm IDEA: XBRL DOCUMENT v3.24.3
Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Astellas Agreement [Member] | Japan [Member] | License Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration $ 100,300  
Astellas Agreement [Member] | Japan [Member] | Co-development, information sharing & committee services [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 17,100  
Astellas Agreement [Member] | Europe [Member] | License Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 619,000  
Astellas Agreement [Member] | Europe [Member] | Co-development, information sharing & committee services [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 287,700  
AstraZeneca Agreements [Member]    
Disaggregation of Revenue [Line Items]    
Deferred Revenue 146,967 $ 179,851
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | License Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 344,500  
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | Co-development, information sharing & committee services [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration 625,500  
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | China performance obligation [Member]    
Disaggregation of Revenue [Line Items]    
Total Consideration $ 458,100